

## DIRECTOR OF FINANCE

### COMPANY

Hepatiq Inc. makes HEPATIQ<sup>®</sup> – The Ultimate Liver Test™. This software product uses standard Technetium-99m sulfur colloid SPECT images for the diagnosis, staging, prognosis, interventions and monitoring of liver disease. Customers are hospitals and imaging centers equipped with a SPECT scanner. We have developed the HEPATIQ product, secured patents & trademarks, obtained FDA clearance, and are now generating recurring revenues from customers.

Currently, physicians use blood tests, elastography and biopsies to assess liver disease. All of these tests estimate the extent of fibrosis (or scarring) in the liver. None measure the remaining function. It is important to measure the residual function as the liver can regenerate and blood flow to the liver can increase to get more function out of what is remaining. Clinical research studies show that function outperforms fibrosis in the prediction of disease outcomes. HEPATIQ is the only product on the market that precisely quantifies liver functional reserve.

### DUTIES

The Director of Finance will help the company with financing the growth of operations and eventually an IPO or sale. He or she will supervise the accounting staff.

The work environment provides daily opportunities to interact with the financial community while participating with all company departments. Job requires high standards of quality and the ability to act quickly.

### QUALIFICATIONS

- At least 5 years of finance and accounting experience.
- Track record of improving profitability of operating departments.
- Bachelor's degree or equivalent.
- Able to work at company headquarters in Irvine, California.
- Strong analytical skills, welcomes responsibility and is decisive.

### WHY JOIN HEPATIQ?

- HEPATIQ is the only FDA cleared quantitative liver function product on the market
- Other tests estimate liver fibrosis; function outperforms fibrosis in predicting outcomes
- 4 issued US patents and 5 foreign patents; 9 registered trademarks
- Liver diagnostics market is \$8 billion/year worldwide, growing 12% per year
- Customer gets get reimbursement from patients' insurance and pays us.
- Pure software product; zero manufacturing cost resulting in large gross margins

### TO APPLY

This is a ground floor opportunity – become part of a team whose vision is better diagnosis and prognosis of chronic liver disease. To apply, please send resume and compensation requirements to Mr. Dipu Ghosh, CEO, at [dghosh@hepatiq.com](mailto:dghosh@hepatiq.com).